Overview

Webcast ImageWebcast
Clovis Oncology, Inc. at 35th Annual J.P. Morgan Healthcare Conference (Replay)
01/10/17 at 2:30 p.m. PT
Clovis Oncology, Inc. at 35th Annual J.P. Morgan Healthcare Conference
Tuesday, January 10, 2017 2:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to personalized medicine – to deMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$57.11
Change (%) Stock is Up 0.49 (0.87%)
Intraday High$59.74
Intraday Low$56.33
Volume2,494,865
Data as of 01/19/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
01/09/17Clovis Oncology to Present at the 35th Annual J.P. Morgan Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 9, 2017-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 2:30 PM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A live webcast of the presentation and breakout session can be accessed thro... 
Printer Friendly VersionDownload PDF
01/04/17Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 4, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 750,000 shares. The offering, including the sale of the additional shares, is expected to close on January 9, 2017, subject to customary closing conditions. Clovis Oncology intends to use t... 
Printer Friendly VersionDownload PDF
01/03/17Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 3, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.00 per share, before underwriting discounts and commissions. The size of the offering was upsized from $175 million to $205 million. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock from Clovis Oncol... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.